SCHEMBL7235245

SCHEMBL7235245

COC(=O)c1ccc2c(c1)/C(=C(\C)Nc1ccc(CN3CCCCC3)cc1)C(=O)N2

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
KDM4E B2RXH2 1/20 0.49
LMNA P02545 3/20 0.48
KMT2A Q03164 2/20 0.48
MAPT P10636 2/20 0.47
GAA P10253 1/20 0.47
HPGD P15428 1/20 0.47
MEN1 O00255 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
MAPK1 P28482 1/20 0.46
CHKA P35790 1/20 0.45
TNF P01375 1/20 0.45
GLA P06280 1/20 0.44
ATM Q13315 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2120501 0.93 ALDH1A1 (0.49) ALDH1A1KDM4ELMNAKMT2AMAPT
SCHEMBL2120504 0.93 ALDH1A1 (0.49) ALDH1A1KDM4ELMNAKMT2AMAPT
SCHEMBL7234781 0.91 KDM4E (0.51) ALDH1A1KDM4ELMNAKMT2AGAA
SCHEMBL7982079 0.89 ALDH1A1 (0.51) ALDH1A1KDM4ELMNAKMT2AMAPT
SCHEMBL17976195 0.89 LMNA (0.47) ALDH1A1KDM4ELMNAKMT2AMAPT
SCHEMBL17976178 0.88 LMNA (0.46) ALDH1A1KDM4ELMNAKMT2AMAPT
SCHEMBL3161761 0.88 KMT2A (0.52) ALDH1A1LMNAKMT2AMAPTGAA
SCHEMBL3161752 0.88 KMT2A (0.52) ALDH1A1LMNAKMT2AMAPTGAA
SCHEMBL17976228 0.88 LMNA (0.46) ALDH1A1KDM4ELMNAKMT2AMAPT
SCHEMBL17976485 0.88 LMNA (0.44) ALDH1A1KDM4ELMNAKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6545035-B1 Having effect on various kinases and cycline/CDK complexes and on the proliferation of various tumour cells. BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-04-08 US disclosed